Cargando…
The Efficacy and Safety of 17α-Estradiol (Ell-Cranell® alpha 0.025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comparative, Phase IV Study
BACKGROUND: There are several commercially available agents to treat female pattern hair loss (FPHL), including minoxidil solution, anti-androgen agents and mineral supplements. However, these treatments are not always satisfactory. We report the results of a clinical trial of 17α-estradiol (Ell-Cra...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Dermatological Association; The Korean Society for Investigative Dermatology
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412238/ https://www.ncbi.nlm.nih.gov/pubmed/22879713 http://dx.doi.org/10.5021/ad.2012.24.3.295 |
_version_ | 1782239942021218304 |
---|---|
author | Kim, Jae-Hong Lee, Sung Yul Lee, Hae-Jin Yoon, Na-Young Lee, Won-Soo |
author_facet | Kim, Jae-Hong Lee, Sung Yul Lee, Hae-Jin Yoon, Na-Young Lee, Won-Soo |
author_sort | Kim, Jae-Hong |
collection | PubMed |
description | BACKGROUND: There are several commercially available agents to treat female pattern hair loss (FPHL), including minoxidil solution, anti-androgen agents and mineral supplements. However, these treatments are not always satisfactory. We report the results of a clinical trial of 17α-estradiol (Ell-Cranell® alpha 0.025%) solution to Korean female patients with FPHL. OBJECTIVE: This study was designed to examine the efficacy and safety of Ell-Cranell® alpha 0.025% solution in Korean female patients with FPHL. METHODS: A total of 53 women, 18 to 55 years old, applied topical Ell-Cranell® alpha 0.025% solution once daily for 8 months. Efficacy was evaluated by the change of hair counts and diameter, subjective assessment, and photographic assessment by investigators. RESULTS: Hair counts and diameter from baseline to 4 and 8 months after treatment increased in treated patients and these changes were statistically significant (p<0.0001). 17α-estradiol (Ell-Cranell® alpha 0.025%) solution showed significant improvement by subjective self-assessment and by investigator photographic assessment. Ell-Cranell® alpha 0.025% solution was well tolerated over 8-months period. CONCLUSION: This study showed that Ell-Cranell® alpha 0.025% solution is a safe and effective agent for Korean women with FPHL. |
format | Online Article Text |
id | pubmed-3412238 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Korean Dermatological Association; The Korean Society for Investigative Dermatology |
record_format | MEDLINE/PubMed |
spelling | pubmed-34122382012-08-09 The Efficacy and Safety of 17α-Estradiol (Ell-Cranell® alpha 0.025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comparative, Phase IV Study Kim, Jae-Hong Lee, Sung Yul Lee, Hae-Jin Yoon, Na-Young Lee, Won-Soo Ann Dermatol Original Article BACKGROUND: There are several commercially available agents to treat female pattern hair loss (FPHL), including minoxidil solution, anti-androgen agents and mineral supplements. However, these treatments are not always satisfactory. We report the results of a clinical trial of 17α-estradiol (Ell-Cranell® alpha 0.025%) solution to Korean female patients with FPHL. OBJECTIVE: This study was designed to examine the efficacy and safety of Ell-Cranell® alpha 0.025% solution in Korean female patients with FPHL. METHODS: A total of 53 women, 18 to 55 years old, applied topical Ell-Cranell® alpha 0.025% solution once daily for 8 months. Efficacy was evaluated by the change of hair counts and diameter, subjective assessment, and photographic assessment by investigators. RESULTS: Hair counts and diameter from baseline to 4 and 8 months after treatment increased in treated patients and these changes were statistically significant (p<0.0001). 17α-estradiol (Ell-Cranell® alpha 0.025%) solution showed significant improvement by subjective self-assessment and by investigator photographic assessment. Ell-Cranell® alpha 0.025% solution was well tolerated over 8-months period. CONCLUSION: This study showed that Ell-Cranell® alpha 0.025% solution is a safe and effective agent for Korean women with FPHL. Korean Dermatological Association; The Korean Society for Investigative Dermatology 2012-08 2012-07-25 /pmc/articles/PMC3412238/ /pubmed/22879713 http://dx.doi.org/10.5021/ad.2012.24.3.295 Text en Copyright © 2012 The Korean Dermatological Association and The Korean Society for Investigative Dermatology http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Kim, Jae-Hong Lee, Sung Yul Lee, Hae-Jin Yoon, Na-Young Lee, Won-Soo The Efficacy and Safety of 17α-Estradiol (Ell-Cranell® alpha 0.025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comparative, Phase IV Study |
title | The Efficacy and Safety of 17α-Estradiol (Ell-Cranell® alpha 0.025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comparative, Phase IV Study |
title_full | The Efficacy and Safety of 17α-Estradiol (Ell-Cranell® alpha 0.025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comparative, Phase IV Study |
title_fullStr | The Efficacy and Safety of 17α-Estradiol (Ell-Cranell® alpha 0.025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comparative, Phase IV Study |
title_full_unstemmed | The Efficacy and Safety of 17α-Estradiol (Ell-Cranell® alpha 0.025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comparative, Phase IV Study |
title_short | The Efficacy and Safety of 17α-Estradiol (Ell-Cranell® alpha 0.025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comparative, Phase IV Study |
title_sort | efficacy and safety of 17α-estradiol (ell-cranell® alpha 0.025%) solution on female pattern hair loss: single center, open-label, non-comparative, phase iv study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412238/ https://www.ncbi.nlm.nih.gov/pubmed/22879713 http://dx.doi.org/10.5021/ad.2012.24.3.295 |
work_keys_str_mv | AT kimjaehong theefficacyandsafetyof17aestradiolellcranellalpha0025solutiononfemalepatternhairlosssinglecenteropenlabelnoncomparativephaseivstudy AT leesungyul theefficacyandsafetyof17aestradiolellcranellalpha0025solutiononfemalepatternhairlosssinglecenteropenlabelnoncomparativephaseivstudy AT leehaejin theefficacyandsafetyof17aestradiolellcranellalpha0025solutiononfemalepatternhairlosssinglecenteropenlabelnoncomparativephaseivstudy AT yoonnayoung theefficacyandsafetyof17aestradiolellcranellalpha0025solutiononfemalepatternhairlosssinglecenteropenlabelnoncomparativephaseivstudy AT leewonsoo theefficacyandsafetyof17aestradiolellcranellalpha0025solutiononfemalepatternhairlosssinglecenteropenlabelnoncomparativephaseivstudy AT kimjaehong efficacyandsafetyof17aestradiolellcranellalpha0025solutiononfemalepatternhairlosssinglecenteropenlabelnoncomparativephaseivstudy AT leesungyul efficacyandsafetyof17aestradiolellcranellalpha0025solutiononfemalepatternhairlosssinglecenteropenlabelnoncomparativephaseivstudy AT leehaejin efficacyandsafetyof17aestradiolellcranellalpha0025solutiononfemalepatternhairlosssinglecenteropenlabelnoncomparativephaseivstudy AT yoonnayoung efficacyandsafetyof17aestradiolellcranellalpha0025solutiononfemalepatternhairlosssinglecenteropenlabelnoncomparativephaseivstudy AT leewonsoo efficacyandsafetyof17aestradiolellcranellalpha0025solutiononfemalepatternhairlosssinglecenteropenlabelnoncomparativephaseivstudy |